Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


High temperature Hall measurement setup for thin film characterization.

Adnane L, Gokirmak A, Silva H.

Rev Sci Instrum. 2016 Jul;87(7):075117. doi: 10.1063/1.4959222.


High temperature setup for measurements of Seebeck coefficient and electrical resistivity of thin films using inductive heating.

Adnane L, Williams N, Silva H, Gokirmak A.

Rev Sci Instrum. 2015 Oct;86(10):105119. doi: 10.1063/1.4934577.


Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.

Petrul HM, Schatz CA, Kopitz CC, Adnane L, McCabe TJ, Trail P, Ha S, Chang YS, Voznesensky A, Ranges G, Tamburini PP.

Mol Cancer Ther. 2012 Feb;11(2):340-9. doi: 10.1158/1535-7163.MCT-11-0523. Epub 2011 Dec 6.


Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.

Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Sch├╝tz G, Thierauch KH, Zopf D.

Int J Cancer. 2011 Jul 1;129(1):245-55. doi: 10.1002/ijc.25864. Epub 2011 Apr 22.


Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.

Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M.

Mol Cancer Ther. 2008 Oct;7(10):3129-40. doi: 10.1158/1535-7163.MCT-08-0013. Review.


Recent advances in the research and development of RAF kinase inhibitors.

Smith RA, Dumas J, Adnane L, Wilhelm SM.

Curr Top Med Chem. 2006;6(11):1071-89. Review.


BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.

Cancer Res. 2004 Oct 1;64(19):7099-109.

Supplemental Content

Loading ...
Support Center